Parallax Volatility Advisers’s Heron Therapeutics HRTX Stock Holding History

Parallax Volatility Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$286K	–	3052
2022 Q1	$286K	Buy	+50,000	New	+$366K	﹤0.01%	2076
2019 Q2	–	Sell	-25,000	Closed	-$611K	–	3060
2019 Q1	$611K	Buy	+25,000	New	+$654K	﹤0.01%	1453
2018 Q3	–	Sell	-193,000	Closed	-$7.5M	–	2992
2018 Q2	$7.5M	Buy	+193,000	New	+$6.14M	0.01%	509
2016 Q3	–	Sell	-20,000	Closed	-$361K	–	3309
2016 Q2	$361K	Buy	+20,000	New	+$390K	﹤0.01%	1596
2015 Q4	–	Sell	-63,000	Closed	-$1.54M	–	3301
2015 Q3	$1.54M	Buy	+63,000	New	+$2.1M	﹤0.01%	1128

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Parallax Volatility Advisers's HRTX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Heron Therapeutics (HRTX) in Q1 2018, closing a stake of 6,888 shares — an estimated $125K sold.

Parallax Volatility Advisers first reported a position in HRTX in Q4 2015 and held it in 8 quarters. The position peaked at $125K in Q4 2017. 152 funds tracked by Wall St. Rank hold HRTX as of Q1 2018.

Parallax Volatility Advisers reported no remaining Heron Therapeutics position as of Q1 2018 after selling out during the quarter.
Parallax Volatility Advisers sold 6,888 Heron Therapeutics shares in Q1 2018, an estimated $125K.
Parallax Volatility Advisers first reported a position in Heron Therapeutics in Q4 2015 and held it in 8 quarters.
Parallax Volatility Advisers's Heron Therapeutics position peaked at $125K in Q4 2017.
152 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.